Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Using harmless bacteria to fight cancer

05.04.2016

A study by HZI scientists suggests that probiotic E. coli could be used as a therapeutic agent against cancer

Several bacterial species have pledged promise in fighting tumors. However, most of them are pathogens. In order to use them as a weapon against cancer and other diseases in humans, researchers must find a balance between their therapeutic aggressiveness and safety for the patient.


Probiotic E. coli could be used as a therapeutic agent against cancer.

HZI / Rohde

To overcome this problem, researchers at the Helmholtz Centre for Infection Research (HZI) have shifted their focus from pathogenic bacteria to those with a proven safety profile, namely probiotic E. coli.

First tests in mice indicate that the probiotic bacteria were indeed efficiently targeting the tumors without generating a toxic effect. The research has been published in the journal “Oncotarget” and opens the door to a new approach in fighting cancer.

Cancers are among the leading causes of morbidity and mortality worldwide. Despite improving treatments such as chemotherapy the disease is still advancing. According to statistics of the World Health Organisation from 2012 (WHO) the number of new cases is expected to rise by about 70 percent over the next two decades. Thus, there is an urgent need for new therapeutic approaches. One possibility is to use pathogenic bacteria such as Salmonella.

‘However, there is one big problem when applying them to human patients’, says Dr Dino Kocijancic, scientist in the department of “Molecular Immunology” at the HZI. ‘We have to modify the bacteria in a way that they do not cause harm. The first clinical trials showed that this is possible but hardly without limiting the therapeutic effects’. In this particular case, the attenuation for safety was too extensive so that the therapeutic power was lost.

To solve this problem the scientists tried an opposing strategy by using probiotic bacteria, which are beneficial rather than harmful to the human host. Kocijancic and his colleagues chose E. coli probiotics which are used by millions of people to treat intestinal disorders. Furthermore, those bacterial strains are already well-studied making it easy to give them new properties and functions.

When testing their approach in tumor bearing mice the researchers found that the E. coli probiotics, notably Symbioflor-2, were very efficient in targeting tumors.

‘This indicates that they are holding a great potential in solid tumor therapy even though their therapeutic potency might be slightly lower than that of Salmonella’, says Kocijancic. ‘However, their superior tumor specificity and the fact that they do not need to be weakened will allow us to use them as bio-vehicles delivering therapeutic molecules into tumors’.

The research indicates that a probiotic therapeutic strain more readily tolerated by an immune compromised cancer patient may allow for systemic application and higher dosing compared to the vastly explored attenuated Salmonella. ’We are sure that this will prove correct in further tests. Thus, our new approach will more readily utilize the advantages of bacteria mediated tumor therapy’, says Dr Siegfried Weiss, head of the research group.

Publication:
Therapy of solid tumors using probiotic Symbioflor-2 – restraints and potential. Dino Kocijancic, Sebastian Felgner, Michael Frahm, Ronja-Melinda Komoll, Aida Iljazovic, Vinay Pawar, Manfred Rohde, Ulrike Heise, Kurt Zimmermann, Florian Gunzer, Juliane Hammer, Katja Crull, Sara Leschner, Siegfried Weiss. Oncotarget; 2016 Mar 10. DOI: 10.18632/oncotarget.8027.

Weitere Informationen:

https://www.helmholtz-hzi.de/en/news_events/news/view/article/complete/using_har... - press release

Susanne Thiele | Helmholtz-Zentrum für Infektionsforschung

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

3rd Symposium on Driving Simulation

23.10.2017 | Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

 
Latest News

Taming 'wild' electrons in graphene

23.10.2017 | Physics and Astronomy

Mountain glaciers shrinking across the West

23.10.2017 | Earth Sciences

Scientists track ovarian cancers to site of origin: Fallopian tubes

23.10.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>